| ASCO Update on Bone-Modifying Drugs in Metastatic Breast Cancer - Medscape |
|
|
Medscape In addition, the toxicity profiles are different — for example, denosumab is associated with a risk for hypocalcemia, and zoledronic acid and pamidronate are associated with a risk for renal toxicity and require renal function monitoring. |